Zepbound 5 MG/0.5 ML pen 0.5ML
Ended Awarded
- Contract number
- SPE2DB25FXD13
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $22,765
Award facts
- Contract value 100% obligated
- $22,764.56 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $22,764.56 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pens with an ultimate completion date of September 4, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement and fulfills this order from its corporate office location in the same city. The delivery order is a child contract under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999.99 million through December 2026, which provides comprehensive pharmaceutical support to military and federal healthcare systems globally.
Zepbound is a GLP-1 receptor agonist used for weight management and is supplied through AmerisourceBergen Drug Corp's extensive pharmaceutical portfolio available under the DLA Troop Support Medical prime vendor contract. The company's federal procurement profile demonstrates consistent capability in delivering specialty medications, brand-name drugs, and medical supplies across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other government healthcare customers. AmerisourceBergen Drug Corp's substantial IDC with DLA reflects its position as a preferred provider for federal medical supply needs and positions it well within the strategic landscape of military pharmaceutical procurement operations.
Quick answers
Who was awarded contract SPE2DB25FXD13?
SPE2DB25FXD13 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on September 3, 2025.
How much is contract SPE2DB25FXD13 worth?
The government has obligated $22,765 on SPE2DB25FXD13.
Is contract SPE2DB25FXD13 an order under another contract?
Yes. SPE2DB25FXD13 is a delivery order under SPE2DB22D3501, an indefinite delivery contract.
Was contract SPE2DB25FXD13 competed?
The extent of competition for SPE2DB25FXD13 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award